甲磺酸阿帕替尼治疗化疗失败晚期恶性肿瘤近期疗效观察

The Recent Curative Effect of Apatinib Methsulfonate on the Treatment of Late-stage Malignant Tumor

目的观察甲磺酸阿帕替尼治疗化疗失败晚期恶性肿瘤的近期疗效。方法选择我院肿瘤科2015年1月—2016年12月曾接受过二线及二线以上化疗失败的晚期恶性肿瘤患者25例作为研究对象。所有患者均给予甲磺酸阿帕替尼治疗,比较治疗前、后肿瘤的变化及血清癌胚抗原水平。结果治疗前,患者血清癌胚抗原指数为(22.43±1.87)ng/ml,治疗后为(13.55±0.98)ng/ml,治疗前后对比,差异具有统计学意义(P<0.05)。结论晚期恶性肿瘤患者应用甲磺酸阿帕替尼有利于强化临床疗效,延缓肿瘤的进程。

Objective To observe the recent curative effect of apatinib methsulfonate in the treatment of 25 patients with advanced malignant tumors. Methods 25 cases of advanced cancer patients who suffered from second-line and second-line chemotherapy failure in our hospital from January 2015 to December 2016 were selected as the subjects. All patients were given mesylate apatinib treatment, the changes of tumor and serum carcinoembryonic antigen were compared before and after treatment. Results Before treatment, the serum carcinoembryonic antigen index was （22.43±1.87） ng/ml, after treatment （13.55±0.98） ng/ml, before and after treatment, the difference was statistically significant （P 〈 0.05）. Conclusion Apatinib in patients with advanced malignant tumor is beneficial to strengthen clinical effect and delay the process of tumor.